HAIR CARE


and reactivation of the capillary microcirculation), a decrease in the number of hairs in the telogen phase and an increase in those in the anagen phase, and finally, a decrease in the activity of the 5α- reductase: thus to obtain healthier hair and greater density on the scalp. Ganother has proven to be effectively active on all these targets. The performed tests have shown indeed that


Ganother exerts on the one hand a beneficial structural action on the follicle, stimulating the protein synthesis from the papilla fibroblasts (+23% at 10 µg/mL after 48h), and helping to restore the correct physiology of the follicle. This is thanks to its antioxidant (GAE: 0.63 mg/ mL) and anti-inflammatory activity (Nitric Oxide scavenging 93% at 5 µL/mL). Interestingly, the scavenging action against the NO radical (a well- known endothelial vasodilator), also restores the correct anabolic and catabolic exchanges at the level of the follicle microcirculation. On the other hand, Ganother has proven


effective in modulating the hair’s life cycle, effectively inhibiting the activity of 5α-reductase (by 14% at a concentration of 0.2 mg/mL), and increasing the hairs in the anagen phase (+ 6%) and decreasing those in telogen phase (-20%), when applied twice per day (84 days) in a 2% hydroalcholic based serum on female volunteers with weak and damaged hair. These demonstrated activities support


and therefore explain the success of the hair- reinforcing action test, which demonstrated Ganother’s ability to increase hair density in vivo during the treatment period (+6%).


References 1. Cör D et al. Antitumour, Antimicrobial, Antioxidant and Antiacetylcholinesterase Effect of Ganoderma Lucidum Terpenoids and Polysaccharides: A Review, Molecules 2018; 23(3):649.


2. Li Y-Q, et al. Anti-hepatitis B activities of PC


73


105 100 95 90 85 80 75


CTRL- 0


DHT average (pg/ml) DHT reduction (%)


585.39 100


0.2


503.72 86


Ganother® µg/ml 0.1


557.89 95.3


0.05


552.06 94.3


Figure 4: Inhibition of 5-α-reductase test. Evaluation of % DHT reduction at different concentrations of the sample.


ganoderic acid from Ganoderma lucidum, Biotechnology Letters 2006; 28: 837–841


3. LH Ren, et al. Anti-atherosclerotic properties of higher mushrooms, a clinico-experimental investigation, Voprosy Pitaniia 1989, 1: 33-36.


4. Ma H-T, et al. Anti-diabetic effects of Ganoderma lucidum, Phytochemistry 2015; 114:109-13


5. Kabir Y, et al. Dietary Effect of Ganoderma lucidum Mushroom on Blood Pressure and Lipid Levels in Spontaneously Hypertensive Rats (SHR), Journal of Nutritional Science and Vitaminology 1988; 34(4):433-8.


HAIR VARIATION % USING 2% GANOTHER® HAIR LOTION 83 81 79 77 75 73 71 0


Anagen Telogen


75.7 24.3


). 42 Time (days)


76.4 23.6


80.6 19.4


84


25 24 23 22 21 20 19 18 17 16 15


6. Kao C, et al. Anti-cancer activities of Ganoderma lucidum: Active ingredients and pathways; In vitro and in vivo protective effect of Ganoderma lucidum polysaccharides on alloxan-induced pancreatic islets damage, Functional Foods in Health & Disease 2013; 3(2)


7. Beretta G, et al. An analytical and theoretical approach for the profiling of the antioxidant activity of essential oils: The case of Rosmarinus officinalis L., Journal of Pharmaceutical and Biomedical Analysis 2011; 55, 1255-1264


HAIR DENSITY AVERAGE (n°/cm2


130 128 126 124 122 120 118 116 114 112 110


0 42 Time (days)


Figure 5: Evaluation of the hair-reinforcing action test. a) evaluation of % hair variation in anagen and telogen phases; b) hair density average values (n°/cm2


www.personalcaremagazine.com January 2021 PERSONAL CARE 84 )


% Hair / time


DHT reduction (%)


n° / cm2


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84